{"id":"W2117355364","doi":"10.1016/s1470-2045(15)00216-8","title":"Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; Internal medicine; Colorectal cancer; Maintenance therapy; Oncology; Clinical endpoint; Progression-free survival; Chemotherapy; Cancer; Randomized controlled trial; Surgery; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001809803,0.00151646,0.002716944,0.0003596574,0.0003228176,0.001059021,0.0008967966,0.001765444,0.007260004],"category_scores_gemma":[0.001412792,0.0006406808,0.002471712,0.0003622566,0.001159896,0.001353362,0.0004997717,0.003539593,0.001147569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001013658,"about_ca_system_score_gemma":0.0009345208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001550597,"about_ca_topic_score_gemma":0.00407691,"domain_scores_codex":[0.9994784,0.0002417228,0.00002986947,0.0001035624,0.00003755299,0.0001088804],"domain_scores_gemma":[0.9994245,0.0001533991,0.0001200474,0.00004976261,0.00003146166,0.0002208949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9747109,0.002361741,0.0004071312,0.0006841407,0.001024123,0.00002620253,0.00005122135,0.0004460185,0.001779506,0.0001488072,0.001351931,0.01700818],"study_design_scores_gemma":[0.9591064,0.03806277,0.0009322424,0.00003665795,0.0004133846,0.00003163919,0.00002159392,0.0003577316,0.0002115269,0.0001838307,0.000628241,0.00001406839],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807093,0.008684373,0.0007504553,0.001467302,0.0008795494,0.002215702,0.001687892,0.0002068493,0.003398583],"genre_scores_gemma":[0.9834912,0.003758027,0.001606392,0.001766755,0.0004501756,0.001996952,0.001996221,0.00004307623,0.004891191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007260004,"threshold_uncertainty_score":0.0242871,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1232492547322935,"score_gpt":0.4226656086118182,"score_spread":0.2994163538795246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}